TSE:MBX

Microbix Biosystems Competitors

C$0.62
+0.01 (+1.64 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
C$0.60
Now: C$0.62
C$0.63
50-Day Range
C$0.52
MA: C$0.58
C$0.63
52-Week Range
C$0.22
Now: C$0.62
C$0.68
Volume219,757 shs
Average Volume188,958 shs
Market CapitalizationC$67.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Microbix Biosystems (TSE:MBX) Vs. MDNA, EMC, NEPT, IMV, FRX, and RVX

Should you be buying MBX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Microbix Biosystems, including Medicenna Therapeutics (MDNA), Emblem (EMC), Neptune Wellness Solutions (NEPT), IMV (IMV), Fennec Pharmaceuticals (FRX), and Resverlogix (RVX).

Medicenna Therapeutics (TSE:MDNA) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Medicenna Therapeutics and Microbix Biosystems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/AN/AC($0.31)-16.18
Microbix BiosystemsC$11.64 million5.83C$-5,581,797.00C($0.05)-12.16

Medicenna Therapeutics has higher earnings, but lower revenue than Microbix Biosystems. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medicenna Therapeutics and Microbix Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicenna TherapeuticsN/AN/AN/A
Microbix BiosystemsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Medicenna Therapeutics and Microbix Biosystems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicenna Therapeutics0000N/A
Microbix Biosystems0000N/A

Summary

Microbix Biosystems beats Medicenna Therapeutics on 3 of the 3 factors compared between the two stocks.

Emblem (CVE:EMC) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Emblem and Microbix Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmblemN/AN/AN/A
Microbix BiosystemsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Emblem and Microbix Biosystems, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emblem0000N/A
Microbix Biosystems0000N/A

Earnings & Valuation

This table compares Emblem and Microbix Biosystems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emblem$5.71 million43.02C$-24,806,020.00($0.19)-9.89
Microbix BiosystemsC$11.64 million5.83C$-5,581,797.00C($0.05)-12.16

Microbix Biosystems has higher revenue and earnings than Emblem. Microbix Biosystems is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

Summary

Microbix Biosystems beats Emblem on 3 of the 5 factors compared between the two stocks.

Microbix Biosystems (TSE:MBX) and Neptune Wellness Solutions (TSE:NEPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Microbix Biosystems and Neptune Wellness Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Microbix BiosystemsN/AN/AN/A
Neptune Wellness SolutionsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Microbix Biosystems and Neptune Wellness Solutions, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Microbix Biosystems0000N/A
Neptune Wellness Solutions00103.00

Neptune Wellness Solutions has a consensus target price of C$4.63, indicating a potential upside of 212.50%. Given Neptune Wellness Solutions' higher probable upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Microbix Biosystems.

Earnings and Valuation

This table compares Microbix Biosystems and Neptune Wellness Solutions' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$11.64 million5.83C$-5,581,797.00C($0.05)-12.16
Neptune Wellness SolutionsC$52.78 million4.64C$-223,415,550.00C($1.35)-1.10

Microbix Biosystems has higher earnings, but lower revenue than Neptune Wellness Solutions. Microbix Biosystems is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

Neptune Wellness Solutions beats Microbix Biosystems on 4 of the 7 factors compared between the two stocks.

IMV (TSE:IMV) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares IMV and Microbix Biosystems' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMVC$3,000.0078,544.76C$-39,136,958.00C($0.58)-6.02
Microbix BiosystemsC$11.64 million5.83C$-5,581,797.00C($0.05)-12.16

Microbix Biosystems has higher revenue and earnings than IMV. Microbix Biosystems is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for IMV and Microbix Biosystems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV04002.00
Microbix Biosystems0000N/A

IMV currently has a consensus target price of C$5.08, indicating a potential upside of 46.07%. Given IMV's higher probable upside, research analysts plainly believe IMV is more favorable than Microbix Biosystems.

Profitability

This table compares IMV and Microbix Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMVN/AN/AN/A
Microbix BiosystemsN/AN/AN/A

Fennec Pharmaceuticals (TSE:FRX) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Fennec Pharmaceuticals and Microbix Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/AN/AN/A
Microbix BiosystemsN/AN/AN/A

Valuation & Earnings

This table compares Fennec Pharmaceuticals and Microbix Biosystems' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$170,000.001,235.91C$-24,910,874.00C($0.96)-8.43
Microbix BiosystemsC$11.64 million5.83C$-5,581,797.00C($0.05)-12.16

Microbix Biosystems has higher revenue and earnings than Fennec Pharmaceuticals. Microbix Biosystems is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Fennec Pharmaceuticals and Microbix Biosystems, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00203.00
Microbix Biosystems0000N/A

Microbix Biosystems (TSE:MBX) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Analyst Recommendations

This is a summary of current recommendations for Microbix Biosystems and Resverlogix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Microbix Biosystems0000N/A
Resverlogix0000N/A

Earnings & Valuation

This table compares Microbix Biosystems and Resverlogix's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$11.64 million5.83C$-5,581,797.00C($0.05)-12.16
ResverlogixN/AN/AN/AC$0.0180.91

Resverlogix has lower revenue, but higher earnings than Microbix Biosystems. Microbix Biosystems is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Microbix Biosystems and Resverlogix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Microbix BiosystemsN/AN/AN/A
ResverlogixN/AN/AN/A

Summary

Resverlogix beats Microbix Biosystems on 2 of the 3 factors compared between the two stocks.


Microbix Biosystems Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MDNA
Medicenna Therapeutics
0.5$5.00+0.6%C$264.51 millionN/A-16.18
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.48+3.4%C$244.93 millionC$52.78 million-1.10Gap Down
IMV logo
IMV
IMV
1.2$3.48+1.7%C$239.70 millionC$3,000.00-6.02
FRX
Fennec Pharmaceuticals
0.5$8.08+7.1%C$210.10 millionC$170,000.00-8.43
RVX
Resverlogix
0.7$0.89+1.1%C$208.25 millionN/A80.91Upcoming Earnings
Gap Down
ATE
Antibe Therapeutics
1.3$4.44+2.5%C$202.05 millionC$9.33 million-5.64Gap Down
ONC
Oncolytics Biotech
1.2$3.72+0.5%C$196.30 millionN/A-6.64Analyst Report
HBP
Helix BioPharma
0.5$0.90+0.0%C$127.02 millionN/A-16.36Gap Down
IPA
ImmunoPrecise Antibodies
0.4$12.56+2.8%C$123.03 millionC$17.18 million-58.69Gap Down
ACST
Acasti Pharma
0.8$0.51+7.8%C$88.79 millionC$81,000.0015.00Gap Up
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.33+6.1%C$58.80 millionC$123,870.00-25.38
PMN
ProMIS Neurosciences
0.5$0.19+5.4%C$56.60 millionC$1,787.00-9.25
COV
Covalon Technologies
0.6$1.32+3.0%C$37.44 millionC$23.84 million-5.55News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.26+5.9%C$34.02 millionC$13.02 million-0.37Gap Up
IGX
IntelGenx Technologies
0.9$0.60+5.0%C$30.87 millionC$1.54 million-7.41
QPT
Quest PharmaTech
0.8$0.11+13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74+5.4%C$21.65 millionC$16.14 million22.42Gap Up
CTX
Crescita Therapeutics
0.6$0.85+1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.17+3.0%C$14.12 millionC$1.34 million-4.71Gap Down
GSD
Devonian Health Group
0.5$0.26+3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.09+11.8%C$12.70 millionN/A-3.86High Trading Volume
NSP
Naturally Splendid Enterprises
0.6$0.07+7.7%C$11.06 millionC$2.03 million-1.51
MPH
Medicure
0.7$1.61+1.9%C$10.80 millionC$12.71 million-1.04
BTI
Bioasis Technologies
0.7$0.34+13.2%C$10.16 millionC$4.12 million30.91High Trading Volume
Gap Up
HEM
Hemostemix
0.6$0.37+1.4%C$9.07 millionN/A-2.20
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.40+7.6%C$6.94 millionC$5.60 million7.31Gap Down
IOT
Innovotech
0.8$0.16+6.3%C$6.52 millionC$1.04 million80.00
BCT
BriaCell Therapeutics
0.5$4.10+2.4%C$4.48 millionN/A-1.32
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.18+0.0%C$0.00C$267.59 million50.75News Coverage
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.